Genetic alterations of FMS-Like Tyrosine Kinase 3 (FLT3) characterize about 25–30% of AML cases [51] as well as several solid tumors such as lung adenocarcinoma and gastrointestinal cancer [52]. This evidence concerns the gene FLT3 and lung adenocarcinoma.